Lactate dehydrogenase-release assay: A reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia

Annals of Hematology

Volumn 70, Issue 3, 1995, Pages 153-158

  Weidmann, E ^a   Brieger, J ^a   Jahn, B ^b   Hoelzer, D ^a   Bergmann, L ^a   Mitrou, P S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Acute myelocytic leukemia; Autologous cytotoxicity; LDH release assay

Indexed keywords

INTERLEUKIN 2; LACTATE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA REMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANTIGENS, CD4; ANTIGENS, CD8; BLAST CRISIS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME TESTS; HUMAN; INTERLEUKIN-2; LACTATE DEHYDROGENASE; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; PHENOTYPE; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0028939609     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/BF01682036     Document Type: Article

References (18)

1. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease in remission
2. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. II. Feasibility of LAK generation in children with active disease and in remission
3. Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance
4. Daily alternating administration of high-dose alpha-2b-interferon and interleukin 2 bolus infusion in metastatic renal cell cancer. A phase-II study
5. Does interleukin 2 have a role in the management of acute leukemia?
6. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine-activated killer cell generation
7. Generation of MHC non-restricted and restricted oncolytic subsets from human bone marrow
8. An enzyme-release assay for natural cytotoxicity
9. Interleukin 2 in cancer therapy
10. Spontaneous human lymphocyte cytotoxicity against human tumor target cells. IX. The quantitation of human natural killer cell activity
11. A progress report on 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or highdose interleukin 2 alone
12. Characterization of human auto-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastases of gastric carcinoma
13. Rapid cytokine release in patients treated with interleukin 2
14. The T-cell receptor V β chain usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma
15. Usage of T-cell receptor V β chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma
16. Constant-infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer